Last reviewed · How we verify

The ropivacaine group — Competitive Intelligence Brief

The ropivacaine group (The ropivacaine group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide). Area: Anesthesia / Pain Management.

marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

The ropivacaine group (The ropivacaine group) — Beijing Tiantan Hospital. Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
The ropivacaine group TARGET The ropivacaine group Beijing Tiantan Hospital marketed Local anesthetic (amide) Voltage-gated sodium channels
extraarticular injection with ropivacaine extraarticular injection with ropivacaine Hvidovre University Hospital marketed Local anesthetic Voltage-gated sodium channels
Articaine / EPINEPHrine Cartridge Articaine / EPINEPHrine Cartridge Universidad de Antioquia marketed Local anesthetic with vasopressor Voltage-gated sodium channels (articaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
nortriptyline + topiramate nortriptyline + topiramate University of California, Irvine marketed Tricyclic antidepressant + anticonvulsant combination Norepinephrine transporter, serotonin transporter, voltage-gated sodium channels, GABA receptors
Lidocaine-Prilocaine Cream 2.5-2.5% Lidocaine-Prilocaine Cream 2.5-2.5% Centre Hospitalier le Mans marketed Local anesthetic Voltage-gated sodium channels
Lidocaine skin wheal Lidocaine skin wheal George Washington University marketed Local anesthetic Voltage-gated sodium channels
Qudexy XR Qudexy XR Upsher-Smith Laboratories marketed Anticonvulsant / Antiepileptic agent GABA-A receptor; voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide) class)

  1. Poznan University of Medical Sciences · 4 drugs in this class
  2. Nantes University Hospital · 3 drugs in this class
  3. Bozyaka Training and Research Hospital · 2 drugs in this class
  4. ASST Gaetano Pini-CTO · 2 drugs in this class
  5. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
  6. Chiang Mai University · 1 drug in this class
  7. Beijing Tiantan Hospital · 1 drug in this class
  8. Complejo Hospitalario Universitario de Granada · 1 drug in this class
  9. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class
  10. China Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The ropivacaine group — Competitive Intelligence Brief. https://druglandscape.com/ci/the-ropivacaine-group. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: